Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2024 | Racial and ethnic disparities in AML: outcomes for Hispanic patients

Sharlene Dong • 26 Jun 2024
EHA 2024
Acute Myeloid Leukemia Leukemia

Sharlene Dong, MD, UT Southwestern Medical Center, Dallas, TX, speaks on racial and ethnic disparities in acute myeloid leukemia (AML). She discusses a study investigating the prognosis of AML in the Hispanic population, which found that Hispanic ethnicity was associated with improved outcomes. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

Related Videos

Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
3:39
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
Marta Coscia • 16 Oct 2026
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
2:00
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
Alexey Danilov • 16 Oct 2026
CaDAnCe-101 trial: exploring the potential of tacabrutideg, a novel BTK degrader, in R/R CLL/SLL
4:56
CaDAnCe-101 trial: exploring the potential of tacabrutideg, a novel BTK degrader, in R/R CLL/SLL
Stephan Stilgenbauer • 16 Oct 2026
Continuous acalabrutinib versus acalabrutinib plus venetoclax in del(17p) or TP53-mutated CLL
1:22
Continuous acalabrutinib versus acalabrutinib plus venetoclax in del(17p) or TP53-mutated CLL
Marta Coscia • 16 Oct 2026
The content of VJHemOnc is intended for healthcare professionals